1, gynecological proprietary Chinese medicine * brand. The company's main business is the production and sales of gynecological proprietary Chinese medicines. At present, the company has a total of 44 production approvals, among which the core products of gynecology are the national essential drugs, the national traditional Chinese medicine protection varieties and the Class A drugs in the National Basic Medical Insurance Drug List. In 2008, its sales exceeded 300 million yuan; Another product of Gynecology Qianjin Capsules has also sold more than 100 million yuan. The company has become a brand of gynecology proprietary Chinese medicine*.
2. The basic drug system will boost the company's growth. There are 8 kinds of gynecological drugs selected in the National Essential Drugs List. The company's gynecological Qianjin tablets and capsules are the only selected heat-clearing and dehumidifying drugs, and the only exclusive variety. Since essential drugs will be fully used in primary care institutions and will be used in proportion to other medical institutions, their sales will increase significantly. Relative to the substantial increase in sales, the price of the company's Qianjin film is unlikely to drop significantly. Because, first of all, Chinese patent medicine is the focus of state support; secondly, the price of the company's Qianjin tablets is already at a low level in similar products, and there is not much room for price reduction; after Zui, the company's Qianjin tablets are high-quality and high-priced products and exclusive varieties, which are greatly reduced in price. The possibility is also small. On the one hand, the sales volume has increased substantially, on the other hand, the price has dropped slightly. The basic drug system will thus benefit the company as a whole, which will boost the company's growth. Moreover, as the company has already done a lot of promotion preparation work in the grassroots township hospitals in the early stage, the positive effects of the policy will soon be reflected.
3. New products are expected to bring breakthroughs. The company has spent 8 years and invested more than 10 million yuan to develop a new product, the milk gel, which is expected to be launched in November. The product has a definite curative effect on chronic cervicitis and cervical erosion, and has a large market space. Another new product of the company, Gynecology Broken Red Drink Capsule, is expected to be launched in October. This product is mainly used to treat functional uterine bleeding. At present, the competitors on the market are only Gongxu Ning of Yunnan Baiyao. Because Gongxu Ning is currently constrained by the lack of raw materials “heavy buildingsâ€, the production capacity is difficult to release, and the company’s broken red drinks do not have the problem of raw material limitation, and its sales are expected to achieve breakthroughs quickly.
4, other business icing on the cake. In addition to the production of gynecological proprietary Chinese medicines, the company's assets include Xiangjiang Pharmaceutical, which produces chemical generic drugs, five-star cinemas, Qianjin Culture Plaza, Qianjin Pharmacy, and Qianjin Logistics. At present, these assets are in a good profit state. Xiangjiang Pharmaceutical is expected to contribute 100 million yuan this year and contribute a net profit of more than 10 million yuan. Qianjin Culture Plaza will contribute more than 5 million yuan in gross profit, and these businesses will have a positive impact on the company's performance.
Spice Novelties Co.,Limited , https://www.wholesale-adult-toys.cn